Literature DB >> 1900266

Multiple primary cancers in patients with squamous cell carcinoma of the oral cavity.

M Saikawa1, S Ebihara, T Yoshizumi, W Ohyama.   

Abstract

During the 27 years between 1962 and 1988, 984 patients visited the National Cancer Center Hospital for previously untreated squamous cell carcinoma of the oral cavity and lip. The records of all these 984 patients were reviewed to determine the incidence of additional primary carcinoma. 1) One hundred and thirty-five additional carcinomas developed in 111 patients (11.2%) during 5,689.2 person-years of observation. The incidence of additional primary carcinoma was 23.7 per 1,000 person-years. 2) The cumulative rate of additional primary carcinoma during the first five years of observation showed a tendency to increase in the most recently treated patients (from 1980 to 1988). 3) The observed-to-expected ratio (O/E ratio) for all sites was 2.77 and this is significantly high (P less than 0.01). The calculation of the O/E ratio for each site revealed significantly high risks in the oral cavity and pharynx, esophagus and skin. The O/E ratio for the oral cavity and pharynx was extremely high (79.45). 4) The O/E ratio for all sites in each year of follow-up was the highest in the first year, stayed nearly constant from the second to 14th years, and decreased gradually afterwards. Significantly high risk was observed until the 13th year of follow-up. Patients with oral squamous cell carcinoma must be under frequent and regular examination for almost 15 years.

Entities:  

Mesh:

Year:  1991        PMID: 1900266      PMCID: PMC5918219          DOI: 10.1111/j.1349-7006.1991.tb01743.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  10 in total

1.  Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.

Authors:  D P SLAUGHTER; H W SOUTHWICK; W SMEJKAL
Journal:  Cancer       Date:  1953-09       Impact factor: 6.860

2.  Statistical methods for studying multiple primary malignant neoplasms.

Authors:  B S Schoenberg; M H Myers
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

3.  Multiple primary tumours in oral cancer.

Authors:  N de Vries; I Van der Waal; G B Snow
Journal:  Int J Oral Maxillofac Surg       Date:  1986-02       Impact factor: 2.789

4.  Second respiratory and upper digestive tract cancers after oral cancer.

Authors:  B S Tepperman; P J Fitzpatrick
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

5.  Multicentric squamous-cell carcinoma of the upper aerodigestive tract.

Authors:  J L Gluckman; J D Crissman; J O Donegan
Journal:  Head Neck Surg       Date:  1980 Nov-Dec

6.  Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract.

Authors:  J L Gluckman; J D Crissman
Journal:  Laryngoscope       Date:  1983-01       Impact factor: 3.325

7.  Multiple primary cancer risk in patients with squamous cell carcinoma of the oral cavity.

Authors:  H Shibuya; S Hisamitsu; S Shioiri; J Horiuchi; S Suzuki
Journal:  Cancer       Date:  1987-12-15       Impact factor: 6.860

8.  Cancer incidence and incidence rates in Japan in 1985--estimates based on data from seven population-based cancer registries. Research Group for Population-based Cancer Registration in Japan.

Authors: 
Journal:  Jpn J Clin Oncol       Date:  1990-06       Impact factor: 3.019

9.  Double and multiple primary cancers in an adult head and neck radiation therapy clinic.

Authors:  J J Kinzie; R B Evans; D Ragan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-11       Impact factor: 7.038

10.  Multiple primary malignancies of the upper aerodigestive system.

Authors:  D P Vrabec
Journal:  Ann Otol Rhinol Laryngol       Date:  1979 Nov-Dec       Impact factor: 1.547

  10 in total
  1 in total

Review 1.  Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma.

Authors:  Ken Omura
Journal:  Int J Clin Oncol       Date:  2014-04-01       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.